Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

Historically, non-small cell lung cancer (NSCLC) treatment involved three modalities: surgery, radiation therapy and chemotherapy. In the last two decades, the treatment landscape of NSCLC has greatly ...

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...

“Lung cancer, though common and serious, still has many misconceptions,” says Ian Bostock, MD, a thoracic surgeon at Miami Cancer Institute in Florida. “Clearing these myths helps patients and ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease.